Mercedes Ingelmo‐Torres
Papers
1
Total Citations
2
H-Index
1
About
Dr. Mercedes Ingelmo‐Torres is a leading researcher in urologic oncology, with a primary focus on prostate cancer biomarkers and liquid biopsy technologies. Her work centers on improving the prediction and monitoring of disease recurrence after radical prostatectomy, addressing critical gaps in personalized cancer care. Her most cited study, "Role of Liquid Biopsy in Progressive PSA Patients after Radical Prostatectomy" (2024, 2 citations), investigates the utility of circulating free DNA (cfDNA) levels as a non-invasive tool to enhance prognostic accuracy beyond traditional clinicopathological parameters. This contribution is particularly impactful because it tackles the challenge of predicting biochemical recurrence in patients with rising PSA levels, offering a more precise, real-time assessment of disease progression. By pioneering liquid biopsy applications in urology, Dr. Ingelmo‐Torres is advancing the shift toward minimally invasive, dynamic monitoring strategies that could ultimately guide treatment decisions and improve outcomes for prostate cancer patients. Her work underscores the transformative potential of molecular biomarkers in clinical practice, positioning her as an emerging voice in precision oncology.
Research Focus
Key Achievements
Top Papers
- 1